Treatment of relapsed urothelial bladder cancer with vinflunine-Reference-Cited by-同舟云学术

Treatment of relapsed urothelial bladder cancer with vinflunine

Published:2016-01 Issue:1 Volume:27 Page:48-53
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Pistamaltzian Nikolaos,Tzannis Kimon,Pissanidou Vassiliki,Peroukidis Stavros,Milaki Georgia,Karavasilis Vasilis,Mitsogiannis Iraklis,Varkarakis Ioannis,Papatsoris Athanasios,Dellis Athanasios,Adamakis Ioannis,Stravodimos Konstantinos,Molyva Dimitra,Athanasiadis Ilias,Androulakis Nikos,Andreadis Charalambos,Kalofonos Charalambos,Mitropoulos Dionisios,Deliveliotis Charalambos,Constantinides Constantinos,Dimopoulos Meletios A.,Bamias Aristotelis

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference23 articles.

1. Systemic chemotherapy in inoperable or metastatic bladder cancer.;Bamias;Ann Oncol,2006

2. . Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors.;Sternberg;Eur J Cancer,2006

3. . Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.;Von der Maase;J Clin Oncol,2000

4. First and second-line therapy for metastatic urothelial carcinoma of the bladder.;Yafi;Curr Oncol,2011

5. . Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.;Sweeney;J Clin Oncol,2006

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study;Current Oncology;2022-08-24

2. Bladder cancer. A retrospective analysis of the use of vinfluvin in real clinical practice;Research and Practical Medicine Journal;2021-06-23

3. Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date;Drug Design, Development and Therapy;2021-02

4. Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date;DRUG DES DEV THER;2021

5. Bladder cancer: treatment after progression. Results of the second retrospective analysis of data on the efficacy of vinflunin in patients with metastatic urothelial cancer in real clinical practice in Russia;Cancer Urology;2020-11-19